Additionally, Vora et al. demonstrated through a screening of 42 CDK4/6 inhibitors that they were able to sensitize PI3KCA mutation-bearing breast cancer cell lines to PI3K inhibitors. This evidence concerns the gene CDK4 and breast carcinoma.